Tilray Brands, Inc.

TLRY Healthcare Drug Manufacturers Specialty & Generic

Tilray Brands, Inc.’s revenue for fiscal 2026 (year ended May 2026) was $915.5 million, up 11.5% from fiscal 2025. In the quarter to August 2026, revenue grew 22.7%, EPS was flat, free cash flow fell 36.6% and total debt rose 43.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

3.04 0.17 −5.30%
Market cap
$474.4M
P/E
0.0×
Fwd P/E
−14.8×
Dividend yield
—
F-score
3/9
Altman Z
−1.96
Beneish M
−2.01
Dividend safety
n/a
Older periods Nov '25 Feb '26 May '26 Aug '26
Piotroski F-Score

+8 more TTM periods

3 3 3 4
ROE
(84.30%) (63.61%) (7.87%) (10.50%)
ROA
(67.01%) (49.09%) (5.52%) (7.45%)
ROIC
(89.19%) (59.65%) (2.27%) (3.21%)
Return on Tangible Assets
(206.60%) (133.90%) (10.90%) (15.75%)
Average Days of Receivables
47.55 50.34 75.42 72.24
Free Cash Flow per Share
(0.56) (1.14) (0.88) (1.31)
Free Cash Flow
(61.79) (128.34) (98.62) (174.45)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 13 Oct 2026